Immunotherapy of head and neck cancer

被引:0
作者
Hoffmann, T. K. [1 ]
机构
[1] Hals Nasen Ohren Univ Klin Essen, D-45147 Essen, Germany
关键词
Immunotherapy; Head and neck cancer; Epidermal growth factor receptor; Monoclonal Antibody; EGFR protein; human; GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; MONOCLONAL-ANTIBODIES; PLUS CETUXIMAB; IMMUNE-SYSTEM; TUMOR-CELLS; ORAL-MUCOSA; IN-VITRO; PHASE-I; EXPRESSION;
D O I
10.1007/s00106-010-2251-2
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The epidermal growth factor receptor (EGFR) is found to be overexpressed in nearly all squamous cell carcinomas of the head and neck (SCCHN). Monoclonal antibodies (mAbs) against EGFR are currently used to treat recurrent or metastatic disease; however, their mode of action is not fully understood. To investigate the immunological effects of anti-EGFR mAb, a three-dimensional spheroid model of EGFR-expressing SCCHN was generated and used to study the effect of anti-EGFR mAb on leukocyte migration towards tumors. The blockade of EGFR by anti-EGFR mAb in EGFR-overexpressing SCCHN cells led to differential expression (array) of several cytokines and chemokines, including the chemokine MCP-1/CCL-2. This was confirmed by quantitative PCR and ELISPOT analyses and shown to be functionally relevant by blocking experiments. These findings demonstrate that anti-EGFR mAb induces leukocyte infiltration to tumor spheroids by up-regulating chemokine expression. This novel mechanism for anti-EGFR mAb action may contribute to the anti-tumor effects of anti-EGFR mAb in vivo.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 31 条
[11]  
FAN Z, 1993, CANCER RES, V53, P4637
[12]   Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomics-based technology [J].
Gires, O ;
Münz, M ;
Schaffrik, M ;
Kieu, C ;
Rauch, J ;
Ahlemann, M ;
Eberle, D ;
Mack, B ;
Wollenberg, B ;
Lang, S ;
Hofmann, T ;
Hammerschmidt, W ;
Zeidler, R .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (10) :1198-1207
[13]   Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival [J].
Grandis, JR ;
Melhem, MF ;
Gooding, WE ;
Day, R ;
Holst, VA ;
Wagener, MM ;
Drenning, SD ;
Tweardy, DJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :824-832
[14]  
Hoffmann T, 1997, ANTICANCER RES, V17, P4419
[15]   A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration [J].
Hoffmann, Thomas K. ;
Schirlau, Kerstin ;
Sonkoly, Enikoe ;
Brandau, Sven ;
Lang, Stephan ;
Pivarcsi, Andor ;
Balz, Vera ;
Mueller, Anja ;
Homey, Bernhard ;
Boelke, Edwin ;
Reichert, Torsten ;
Friebe-Hoffmann, Ulrike ;
Greve, Jens ;
Schuler, Patrick ;
Scheckenbach, Kathrin ;
Schipper, Joerg ;
Bas, Murat ;
Whiteside, Theresa L. ;
Bier, Henning .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (11) :2589-2596
[16]  
Hoffmann TK, 2005, HNO, V53, P285, DOI 10.1007/s00106-004-1167-0
[17]   Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck [J].
Hoffmann, TK ;
Bier, H ;
Whiteside, TL .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (12) :1055-1067
[18]   Serum level and tissue expression of c-erbB-1 and c-erbB-2 protooncogene products in patients with squamous cell carcinoma of the head and neck [J].
Hoffmann, TK ;
Balló, H ;
Braunstein, S ;
Van Lierop, A ;
Wagenmann, M ;
Bier, H .
ORAL ONCOLOGY, 2001, 37 (01) :50-56
[19]   CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY [J].
KOHLER, G ;
MILSTEIN, C .
NATURE, 1975, 256 (5517) :495-497
[20]  
Liu B, 2000, BRIT J CANCER, V82, P1991